申请人:Millennium Pharmaceuticals, Inc.
公开号:US06548499B1
公开(公告)日:2003-04-15
Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.
喹喔啉化合物以及其制备方法和药物组合物被描述,这些化合物可作为白细胞介素-8(IL-8)受体拮抗剂,并可用于治疗趋化因子介导的疾病,其中趋化因子结合到IL-8a(CXCR1)或b(CXCR2)受体,例如选自牛皮癣、特应性疾病综合征、关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、胃溃疡、脓毒性休克、内毒素休克、革兰氏阴性败血症、毒性休克综合征、中风、心脏和肾脏再灌注损伤、肾小球肾炎或血栓形成,阿尔茨海默病、移植物宿主反应、移植排斥反应或过敏性疾病的趋化因子介导的疾病。